Literature DB >> 23205276

EGFR inhibition and more: a new generation growing up.

Deborah Enting1, James Spicer.   

Abstract

Entities:  

Year:  2012        PMID： 23205276      PMCID： PMC3506792          DOI： 10.3978/j.issn.2072-1439.2012.10.04

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  11 in total

1.  Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

Authors:  Vincent A Miller; Vera Hirsh; Jacques Cadranel; Yuh-Min Chen; Keunchil Park; Sang-We Kim; Caicun Zhou; Wu-Chou Su; Mengzhao Wang; Yan Sun; Dae Seog Heo; Lucio Crino; Eng-Huat Tan; Tsu-Yi Chao; Mehdi Shahidi; Xiuyu Julie Cong; Robert M Lorence; James Chih-Hsin Yang
Journal:  Lancet Oncol       Date:  2012-03-26       Impact factor: 41.316

Review 2.  Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.

Authors:  William Pao; Juliann Chmielecki
Journal:  Nat Rev Cancer       Date:  2010-10-22       Impact factor: 60.716

3.  Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

Authors:  Lecia V Sequist; Belinda A Waltman; Dora Dias-Santagata; Subba Digumarthy; Alexa B Turke; Panos Fidias; Kristin Bergethon; Alice T Shaw; Scott Gettinger; Arjola K Cosper; Sara Akhavanfard; Rebecca S Heist; Jennifer Temel; James G Christensen; John C Wain; Thomas J Lynch; Kathy Vernovsky; Eugene J Mark; Michael Lanuti; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Sci Transl Med       Date:  2011-03-23       Impact factor: 17.956

4.  Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

Authors:  Suresh S Ramalingam; Fiona Blackhall; Maciej Krzakowski; Carlos H Barrios; Keunchil Park; Isabel Bover; Dae Seog Heo; Rafael Rosell; Denis C Talbot; Richard Frank; Stephen P Letrent; Ana Ruiz-Garcia; Ian Taylor; Jane Q Liang; Alicyn K Campbell; Joseph O'Connell; Michael Boyer
Journal:  J Clin Oncol       Date:  2012-07-02       Impact factor: 44.544

5.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Authors:  William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

6.  Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.

Authors:  Jenn-Yu Wu; Shang-Gin Wu; Chih-Hsin Yang; Chien-Hung Gow; Yih-Leong Chang; Chong-Jen Yu; Jin-Yuan Shih; Pan-Chyr Yang
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

7.  BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.

Authors:  D Li; L Ambrogio; T Shimamura; S Kubo; M Takahashi; L R Chirieac; R F Padera; G I Shapiro; A Baum; F Himmelsbach; W J Rettig; M Meyerson; F Solca; H Greulich; K-K Wong
Journal:  Oncogene       Date:  2008-04-14       Impact factor: 9.867

Review 8.  Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Authors:  Jeffrey A Engelman; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

9.  Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Authors:  Manabu Soda; Young Lim Choi; Munehiro Enomoto; Shuji Takada; Yoshihiro Yamashita; Shunpei Ishikawa; Shin-ichiro Fujiwara; Hideki Watanabe; Kentaro Kurashina; Hisashi Hatanaka; Masashi Bando; Shoji Ohno; Yuichi Ishikawa; Hiroyuki Aburatani; Toshiro Niki; Yasunori Sohara; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Nature       Date:  2007-07-11       Impact factor: 49.962

10.  PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.

Authors:  Jeffrey A Engelman; Kreshnik Zejnullahu; Christopher-Michael Gale; Eugene Lifshits; Andrea J Gonzales; Takeshi Shimamura; Feng Zhao; Patrick W Vincent; George N Naumov; James E Bradner; Irene W Althaus; Leena Gandhi; Geoffrey I Shapiro; James M Nelson; John V Heymach; Matthew Meyerson; Kwok-Kin Wong; Pasi A Jänne
Journal:  Cancer Res       Date:  2007-12-15       Impact factor: 13.312
View more
  1 in total

1.  Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer.

Authors:  Aiqin Gu; Chunlei Shi; Liwen Xiong; Tianqing Chu; Jun Pei; Baohui Han
Journal:  Chin J Cancer Res       Date:  2013-02       Impact factor: 5.087
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.